


**VC-backed** technology company developing disruptive technologies to boost recombinant biologics production using proprietary technologies based on Baculovirus vector expression systems (BVES) in insect cells.

Supported by a first in class Strategic Advisory Board combining investment and operational experience in developing companies in animal and human health.

Two proprietary and patented technology platforms, Top-Bac® and CrisBio®, to respond to industry's challenges in the production of biologics: development time, scalability, versatility and cost.

Data available in various protein classes and indications across Animal Health, Human Health and Diagnostics.



**We aim to transform protein production to allow universal access to biologics.**

# AREAS OF FOCUS



## Animal Health

20 years' experience in the development and production of animal vaccines.

200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. First dossier for a veterinary vaccine produced using CrisBio® under review by EMA.



## Human Health

Building on experience in animal health, Algenex is expanding the production of proteins into human health to fully exploit the potential of its technology platforms

# Animal Health

We offer a broad portfolio of innovative veterinary solutions for livestock care based on proprietary technologies.

Algenex has more than 20 years' experience in the veterinary sector and is focused on developing and producing veterinary vaccines using its TopBac® and CrisBio® technology platforms.

We have successfully produced more than 200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies and achieved proof-of-concept in more than 20 indications across most livestock species.

The first dossier for a veterinary vaccine produced in CrisBio® is currently being reviewed by the European Medicines Agency (EMA) with potential approval in 2021.

## Benefits of using CrisBio® in the production of proteins for veterinary vaccines:



Linear scalability








Reduced production costs



Increased productivity,  
reaching gram per litre  
yields

## Most advanced projects

				
RHDV	PCV2	BVD	INFLUENZA H7N9	African Swine Fever AB rapid detection test

# Human health

Solutions on large-scale protein production for human healthcare applications such as mass vaccination and diagnostic kits.

## CrisBio® applications in OneHealth



### Prevention of infectious diseases in animals

Up to 75% of new diseases affecting people over the past 10 years originated in animals 13 zoonoses are responsible for 2.2 million deaths per year.



### Pandemic preparedness





Requiring rapid response and production scale-up.



### Universal access to biotech products

Simple production process at significantly lower cost allows commercial viability of biotech product in developing economies.

## Most advanced projects

			
<b>INFLUENZA</b> H1N1; H7N9; H5N1	<b>CoV-19</b>	<b>HPV</b>	<b>Anti Human rotavirus VP6</b>

# VACCINES

Algenex has completed a proof of concept study in avian influenza, a zoonotic disease that has the potential to turn into a global pandemic. In this study, Algenex demonstrated its ability to develop a fully functional and safe vaccine in only four months.

Using CrisBio®, Algenex is ideally positioned to produce and supply large quantities of proteins to pharmaceutical companies developing and manufacturing vaccines quickly and at competitive prices. This would enable widespread immunization, in particular in countries with weak economies and less advanced public health systems.